Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model

Neurobiology of Disease

Volumn 68, Issue , 2014, Pages 126-136

  Ongali, Brice ^a   Nicolakakis, Nektaria ^a   Tong, Xin Kang ^a   Aboulkassim, Tahar ^a   Papadopoulos, Panayiota ^a   Rosa Neto, Pedro ^b,c   Lecrux, Clotilde ^a   Imboden, Hans ^d   Hamel, Edith ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Amyloid; Angiotensin receptor blocker (ARB); AT1 receptor; AT4 receptor; FDG PET; Insulin regulated aminopeptidase (IRAP); Memory; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN RECEPTOR; COPPER ZINC SUPEROXIDE DISMUTASE; FLUORODEOXYGLUCOSE F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; LOSARTAN; MANGANESE SUPEROXIDE DISMUTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; ENDOTHELIN 1; ENZYME INHIBITOR; N(OMEGA)-(2-METHOXYETHYL)ARGININE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN LEVEL; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; LASER DOPPLER FLOWMETRY; MALE; MEMORY CONSOLIDATION; MOLECULAR PATHOLOGY; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARASYMPATHETIC INNERVATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECALL; UPREGULATION; VIDEO MICROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; BRAIN; BRAIN CIRCULATION; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARGININE; BLOOD PRESSURE; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LOSARTAN; MALE; MICE; MICE, TRANSGENIC; MUTATION;

EID: 84901047652     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.04.018     Document Type: Article

References (64)

1. Albiston A.L., McDowall S.G., Matsacos D., Sim P., Clune E., Mustafa T., Lee J., Mendelsohn F.A., Simpson R.J., Connolly L.M., Chai S.Y. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001, 276:48623-48626.
2. Albiston A.L., Fernando R.N., Yeatman H.R., Burns P., Ng L., Daswani D., Diwakarla S., Pham V., Chai S.Y. Gene knockout of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiol. Learn. Mem. 2010, 93:19-30.
3. Aucoin J.S., Jiang P., Aznavour N., Tong X.K., Buttini M., Descarries L., Hamel E. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 2005, 132:73-86.
4. Benoist C.C., Wright J.W., Zhu M., Appleyard S.M., Wayman G.A., Harding J.W. Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J. Pharmacol. Exp. Ther. 2011, 339:35-44.
5. Berry C., Touyz R., Dominiczak A.F., Webb R.C., Johns D.G. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H2337-H2365.
6. Braszko J.J., Kułakowska A., Winnicka M.M. Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats. J. Physiol. Pharmacol. 2003, 54:271-281.
7. Braszko J.J., Walesiuk A., Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J. Renin-Angiotensin-Aldosterone Syst. 2006, 7:168-174.
8. Cai H., Griendling K.K., Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 2003, 24:471-478.
9. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puoliväli J., Lesné S., Ashe K.H., Muchowski P.J., Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 2007, 282:23818-23828.
10. Danielyan L., Klein R., Hanson L.R., Buadze M., Schwab M., Gleiter C.H., Frey W.H. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010, 13:195-201.
11. Davies N.M., Kehoe P.G., Ben-Shlomo Y., Martin R.M. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 2011, 26:699-708.
12. deIpolyi A.R., Fang S., Palop J.J., Yu G.Q., Wang X., Mucke L. Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 2008, 29:253-266.
13. Fernando R.N., Albiston A.L., Chai S.Y. The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus-potential role in modulation of glucose uptake in neurones?. Eur. J. Neurosci. 2008, 28:588-598.
14. Ferrington L., Miners J.S., Palmer L.E., Bond S.M., Povey J.E., Kelly P.A.T., Love S., Horsburgh K.J., Kehoe P.G. Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease. Am. J. Transl. Res. 2011, 3(2):197-208.
15. Ferrington L., Palmer L.E., Love S., Horsburgh K.J., Kelly P.A.T., Kehoe P.G. Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. Am. J. Transl. Res. 2012, 4(2):151-164.
16. Fogari R., Mugellini A., Zoppi A., Derosa G., Pasotti C., Fogari E., Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J. Hum. Hypertens. 2003, 17:781-785.
17. Fournier A., Oprisiu-Fournier R., Serot J.M., Godefroy O., Achard J.M., Faure S., Mazouz H., Temmar M., Albu A., Bordet R., Hanon O., Gueyffier F., Wang J., Black S., Sato N. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert. Rev. Neurother. 2009, 9:1413-1431.
18. Frei N., Weissenberger J., Beck-Sickinger A.G., Höfliger M., Weis J., Imboden H. Immunocytochemical localization of angiotensin II receptor subtypes and angiotensin II with monoclonal antibodies in the rat adrenal gland. Regul. Pept. 2001, 101:149-155.
19. Fukumoto H., Tokuda T., Kasai T., Ishigami N., Hidaka H., Kondo M., Allsop D., Nakagawa M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010, 24:2716-2726.
20. Gard P.R. Cognitive-enhancing effects of angiotensin IV. BMC Neurosci. 2008, 9(Suppl. 2):S15.
21. Haydon P.G., Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 2006, 86:1009-1031.
22. Hemming M.L., Selkoe D.J., Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 2007, 26:273-281.
23. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:16-223.
24. Iadecola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E., Younkin S., Borchelt D.R., Hsiao K.K., Carlson G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 1999, 2:157-161.
25. Kazama K., Anrather J., Zhou P., Girouard H., Frys K., Milner T.A., Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ. Res. 2004, 95:1019-1026.
26. Kehoe P.G., Miners S., Love S. Angiotensins in Alzheimer's disease - friend or foe?. Trends Neurosci. 2009, 32:619-628.
27. Kotilinek L.A., Westerman M.A., Wang Q., Panizzon K., Lim G.P., Simonyi A., Lesné S., Falinska A., Younkin L.H., Younkin S.G., Rowan M., Cleary J., Wallis R.A., Sun G.Y., Cole G., Frautschy S., Anwyl R., Ashe K.H. Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain 2008, 131:651-664.
28. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
29. Lesné S.E., Sherman M.A., Grant M., Kuskowski M., Schneider J.A., Bennett D.A., Ashe K.H. Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain 2013, 136:1383-1398.
30. Li Z., Bains J.S., Ferguson A.V. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res. Bull. 1993, 30:33-39.
31. Li N.C., Lee A., Whitmer R.A., Kivipelto M., Lawler E., Kazis L.E., Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465.
32. Liu Y.H., Giunta B., Zhou H.D., Tan J., Wang Y.J. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat. Rev. Neurol. 2012, 8:465-469.
33. Liu J., Liu S., Tanabe C., Maeda T., Zou K., Komano H. Differential effects of angiotensin II receptors blockers on Aβ generation. Neurosci. Lett. 2014, 567:51-56.
34. Ma T., Hoeffer C.A., Wong H., Massaad C.A., Zhou P., Iadecola C., Murphy M.P., Pautler R.G., Klann E. Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci. 2011, 31:5589-5595.
35. Machulda M.M., Ward H.A., Borowski B., Gunter J.L., Cha R.H., O'Brien P.C., Petersen R.C., Boeve B.F., Knopman D., Tang-Wai D.F., Ivnik R.J., Smith G.E., Tangalos E.G., Jack C.R. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 2003, 61:500-506.
36. Maxwell C.J., Hogan D.B. Antihypertensive agents and prevention of dementia. BMJ 2010, 340:b5409.
37. Melrose R.J., Campa O.M., Harwood D.G., Osato S., Mandelkern M.A., Sultzer D.L. The neural correlates of naming and fluency deficits in Alzheimer's disease: an FDG-PET study. Int. J. Geriatr. Psychiatry 2009, 24:885-893.
38. Mentis M.J., Alexander G.E., Krasuski J., Pietrini P., Furey M.L., Schapiro M.B., Rapoport S.I. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am. J. Psychiatry 1998, 155:785-794.
39. Michel M.C., Foster C., Brunner H.R., Liu L. Comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev. 2013, 65:848-908.
40. Mogi M., Li J.M., Tsukuda K., Iwanami J., Min L.J., Sakata A., Fujita T., Iwai M., Horiuchi M. Telmisartan prevented cognitive decline partly due to PPAR-γ activation. Biochem. Biophys. Res. Commun. 2008, 375:446-449.
41. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
42. Nicolakakis N., Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J. Cereb. Blood Flow Metab. 2011, 31:1354-1370.
43. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
44. Ongali B., Nicolakais N., Lecrux C., Aboulkassim T., Rosa-Neto P., Papadopoulos P., Tong X.K., Hamel E. Transgenic mice overexpressing APP and transforming growth factor-β1 feature cognitive and vascular hallmarks of Alzheimer's disease. Am. J. Pathol. 2010, 177:3071-3080.
45. Papadopoulos P., Ongali B., Hamel E. Selective in vivo antagonism of endothelin receptors in transforming growth factor-β1 transgenic mice that mimic the vascular pathology of Alzheimer's disease. Can. J. Physiol. Pharmacol. 2010, 88:652-660.
46. Park L., Anrather J., Zhou P., Frys K., Pitstick R., Younkin S., Carlson G.A., Iadecola C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J. Neurosci. 2005, 25:1769-1777.
47. Park L., Zhou P., Pitstick R., Capone C., Anrather J., Norris E.H., Younkin L., Younkin S., Carlson G., McEwen B.S., Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1347-1352.
48. Sweitzer N.K. Cardiology patient page. What is an angiotensin converting enzyme inhibitor?. Circulation 2003, 108:e16-e18.
49. Takeda S., Sato N., Takeuchi D., Kurinami H., Shinohara M., Niisato K., Kano M., Ogihara T., Rakugi H., Morishita R. Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009, 54:1345-1352.
50. Tong X.K., Nicolakakis N., Kocharyan A., Hamel E. Vascular remodeling versus amyloid β-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 2005, 25:11165-11174.
51. Tong X.K., Lecrux C., Rosa-Neto P., Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J. Neurosci. 2012, 32(14):4705-4715.
52. Tota S., Goel R., Pachauri SD N.R., Najmi A.K., Hanif K., Nath C. Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic neurotransmission, and brain derived neurotrophic factor in rats. Psychopharmacol. (Berl) 2013, 226:57-369.
53. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009, 54:782-787.
54. Wang J., Ho L., Chen L., Zhao Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., Pasinetti G.M. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 2007, 117:3393-3402.
55. Washida K., Ihara M., Nishio K., Fujita Y., Maki T., Yamada M., Takahashi J., Wu X., Kihara T., Ito H., Tomimoto H., Takahashi R. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-{gamma} activation in mice with chronic cerebral hypoperfusion. Stroke 2010, 41:1798-1806.
56. Wayner M.J., Armstrong D.L., Phelix C.F., Wright J.W., Harding J.W. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001, 22:1403-1414.
57. Wiltfang J., Smirnov A., Schnierstein B., Kelemen G., Matthies U., Klafki H.W., Staufenbiel M., Hüther G., Rüther E., Kornhuber J. Improved electrophoretic separation and immunoblotting of beta-amyloid (Aβ) peptides 1-40, 1-42, and 1-43. Electrophoresis 1997, 18:527-532.
58. Wong G.H., Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988, 242:941-944.
59. 4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease. J. Renin-Angiotensin-Aldosterone Syst. 2008, 9:226-237.
60. Wright J.W., Harding J.W. The brain RAS and Alzheimer's disease. Exp. Neurol. 2010, 223:326-333.
61. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
62. Zhang L., Papadopoulos P., Hamel E. Endothelial TRPV4 channels mediate dilation of cerebral arteries: impairment and recovery in cerebrovascular pathologies related to Alzheimer's disease. Br. J. Pharmacol. 2013, 170:661-670.
63. Zhu W.W., Liu X.P., Wu N., Zhao T.T., Zhao Y., Zhang J., Shao J.H. Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats. Mol. Cell. Biochem. 2007, 304:35-43.
64. Zhu D., Shi J., Zhang Y., Wang B., Liu W., Chen Z., Tong Q. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rat. PLoS ONE 2011, 6(1):e16037. (1-9).